Mediolanum International Funds Ltd Acquires 169,026 Shares of Abbott Laboratories $ABT

Mediolanum International Funds Ltd lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 78.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 383,485 shares of the healthcare product maker’s stock after buying an additional 169,026 shares during the period. Mediolanum International Funds Ltd’s holdings in Abbott Laboratories were worth $51,046,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. IMG Wealth Management Inc. raised its position in shares of Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 167 shares in the last quarter. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories in the third quarter worth $29,000. Anfield Capital Management LLC raised its holdings in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares in the last quarter. Delos Wealth Advisors LLC purchased a new position in Abbott Laboratories during the second quarter valued at $32,000. Finally, Copia Wealth Management purchased a new stake in shares of Abbott Laboratories in the 3rd quarter worth about $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a portfolio reset tied to a deal with Exact Sciences that refocuses its cancer diagnostics strategy — investors appear to view the move as a strategic repositioning that could improve longer‑term growth in diagnostics. Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal
• Positive Sentiment: Freedom Capital upgraded ABT from “hold” to “strong‑buy,” a bullish vote that can attract buy‑side interest and support near‑term buying pressure. Freedom Capital upgrade (Zacks)
• Neutral Sentiment: Analyst commentary and feature pieces are framing Abbott as a steady, dividend‑oriented healthcare name, which reinforces income investor interest but is unlikely to drive a large repricing on its own. Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist
• Neutral Sentiment: Coverage pieces and analyst‑call writeups summarize Q4 takeaways and evolving price targets; useful for longer‑term positioning but largely reiterative. How New Price Targets Are Shaping The Evolving Story For Abbott Laboratories (ABT) 5 Insightful Analyst Questions From Abbott’s Q4 Call
• Neutral Sentiment: Updates projecting “decent organic sales growth” for 2026 support baseline expectations for revenue improvement but are not a catalyst by themselves. Decent organic sales growth expected for Abbott Laboratories (ABT) in 2026
• Negative Sentiment: Daiwa Capital Markets lowered its price target to $113 (from $136) while keeping an “outperform” call — a downward PT revision that can cool momentum and signals reduced near‑term upside expectations. Daiwa Securities adjusts Abbott PT to $113
• Negative Sentiment: Leerink Partners cut its target to $119 (from $136) and moved to “market perform,” another analyst downgrade that adds pressure and contributes to today’s mixed tone. Leerink Partners adjusts Abbott PT to $119 TickerReport coverage

Wall Street Analyst Weigh In

ABT has been the subject of a number of analyst reports. Leerink Partners decreased their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday. Citigroup reduced their price objective on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Oppenheimer dropped their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Royal Bank Of Canada lowered their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Barclays lifted their target price on shares of Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $138.40.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $109.31 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The stock has a 50-day simple moving average of $122.77 and a two-hundred day simple moving average of $127.46. The firm has a market capitalization of $190.08 billion, a PE ratio of 29.39, a P/E/G ratio of 1.69 and a beta of 0.72. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.